Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for schizophrenia symptoms
IRCT20210310050660N2Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in schizophrenia comparing Cannabidiol plus usual treatment with Placebo plus usual treatment (2 arms). Primary endpoint: Positive symptoms. Started Apr 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20210310050660N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210310050660N2.